Naloxone Pediatric Dose — Opioid Reversal & Toxicology
Naloxone is a competitive opioid receptor antagonist that rapidly reverses opioid-induced CNS and respiratory depression by displacing opioids from mu, kappa, and delta receptors. It is a cornerstone agent in pediatric toxicology for managing opioid toxicity ranging from iatrogenic respiratory depression to acute narcotic overdose. Onset of action is typically within 1–2 minutes of intravenous administration.
Pediatric Dosing
Dosing strategy depends on the clinical goal: controlled reversal of respiratory depression versus rapid, full reversal of narcotic overdose.
| Indication | Dose (per kg) | Max Single Dose | Repeat Interval |
|---|---|---|---|
| Respiratory Depression (titrated reversal) | 0.001–0.01 mg/kg IV (1–10 mcg/kg) | 0.4 mg/dose | Every 2–3 min PRN |
| Rapid, Full Narcotic Overdose Reversal | 0.1 mg/kg IV | 2 mg/dose | Every 2–3 min PRN |
For respiratory depression, titration using small doses of 1–2 mcg/kg is preferred to limit the risk of precipitating acute pain or opioid withdrawal stress. For a 20 kg child: 20 × 0.001 mg/kg = 0.02 mg (20 mcg) as a conservative starting dose; up to 20 × 0.01 mg/kg = 0.2 mg per dose.
For rapid full reversal, use 0.1 mg/kg IV, not to exceed 2 mg/dose. For a 10 kg child: 10 × 0.1 mg/kg = 1 mg IV per dose. Repeat every 2–3 minutes as needed based on clinical response.
Indications and Clinical Context
Naloxone is indicated for reversal of opioid-induced respiratory depression and sedation in pediatric patients across a spectrum of clinical scenarios, including postoperative opioid over-sedation, accidental ingestion, and intentional overdose. The approach to dosing is intentionally stratified: titrated low doses preserve adequate analgesia and minimize hemodynamic stress in patients receiving therapeutic opioids, while the higher-dose protocol is reserved for acute, life-threatening narcotic overdose requiring immediate, complete reversal consistent with PALS toxicology principles.
In opioid-naive children with accidental ingestion or unknown exposures, prompt full reversal may be necessary to restore ventilation before definitive airway management. Clinicians should anticipate re-narcotization when reversing long-acting opioids, as naloxone’s duration of action (30–90 minutes) may be shorter than the offending agent; repeat dosing or continuous infusion per institutional protocol should be considered.
Administration and Monitoring
The preferred route is intravenous (IV) for fastest onset and most reliable titration. Intraosseous (IO) access is an acceptable alternative when IV access is unavailable. Consult institutional protocol for alternative routes (IM, intranasal) and corresponding dosing adjustments, as these are not addressed in this source description. Administer IV doses as a slow push; for titrated respiratory-depression dosing, dilution may facilitate accurate small-volume administration.
- Monitor respiratory rate, oxygen saturation, level of consciousness, and pain scores continuously after administration.
- Re-narcotization risk: Duration of naloxone may be shorter than the offending opioid; observe for recurrent sedation and repeat dosing as needed.
- Precipitated withdrawal: Rapid full-reversal doses may cause acute opioid withdrawal, including agitation, tachycardia, hypertension, and pulmonary edema in opioid-dependent patients; use titrated dosing when appropriate.
- Max doses: Do not exceed 0.4 mg/dose for respiratory depression or 2 mg/dose for overdose reversal per dose interval without reassessment.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.